Tag Archives: RQI

Top 5 Clean Energy Stocks To Invest In Right Now

What happened 

Shares of natural gas fuel supplier Clean Energy Fuels Corp (NASDAQ:CLNE) jumped as much as 12% in trading Tuesday as oil prices continued to help push the stock higher. At 3:30 p.m. EDT shares were near their high for the day, trading 11.6% higher. 

So what

The ups and downs of crude oil trading can often drive Clean Energy Fuels’ stock and that appears to be what’s happening today. Midday, oil prices spiked on news that the Trump Administration would ban all oil imports from Iran by Nov. 4, 2018. WTI Crude Oil is trading 3.5% higher at $70.45 per barrel and Brent Crude is currently up 2.2% to $76.34 per barrel.

Image source: Getty Images.

Since Clean Energy Fuels’ natural gas products are a direct competitor to diesel, which comes from crude oil, when oil prices rise it makes natural gas more competitive. For today, investors are speculating that rising oil prices will eventually help the company’s financials. 

Top 5 Clean Energy Stocks To Invest In Right Now: Navidea Biopharmaceuticals, Inc.(NAVB)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at last week’s top performing penny stocks, we’ll show you a small-cap stock with real growth potential that just popped up on our radar…

    Penny Stock Current Share Price Last Week’s Gain
    New Age Beverage Corp. (NADAQ: NBEV) $3.94 286.79%
    India Globalization Capital Inc. (NYSE: IGC) $2.18 181.55%
    Ascent Capital Group Inc. (NASDAQ: ASCMA) $2.16 103.85%
    Netlist Inc. (NASDAQ: NLST) $0.73 80.56%
    Oragenics Inc. (NYSE: OGEN) $0.92 71.63%
    Astrotech Corp. (NASDAQ: ASTC) $3.44 68.37%
    Command Security Corp. (NYSE: MOC) $2.77 51.09%
    Oasmia Pharmaceuticals (NASDAQ: OASM) $3.57 50.66%
    NovaBay Pharmaceuticals Inc. (NYSE: NBY) $2.10 48.15%
    Navidea Biopharmaceuticals Inc. (NYSE: NAVB) $0.25 45.72%

    While the gains these stocks made are exciting, they also highlight the danger of investing in penny stocks.

  • [By Money Morning Staff Reports]

    After looking at last week’s top performing penny stocks, we’ll show you a penny stock that’s on the verge of bringing you triple-digit returns…

    Penny Stock Current Share Price Last Week’s Gain
    Orchids Paper Products Co. (NYSE: TIS) $2.60 218.83%
    China Rapid Finance Ltd. (NYSE: XRF) $2.69 69.01%
    Cel-Sci Corp. (NYSE: CVM) $1.21 42.17%
    Regulus Therapeutics Inc. (Nasdaq: RGLS) $0.29 33.40%
    Farmmi Inc. (Nasdaq: FAMI) $3.82 30.51%
    Biolase Inc. (Nasdaq: BIOL) $1.85 29.93%
    Navidea Biopharmaceuticals Inc. (NYSE: NAVB) $0.18 26.99%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $0.92 25.56%
    Inpixon (Nasdaq: INPX) $0.14 24.36%
    JMU Ltd. (Nasdaq: JMU) $1.58 24.05%

    While some of those returns look spectacular, we’re not convinced these penny stocks will keep growing.

Top 5 Clean Energy Stocks To Invest In Right Now: TCP Capital Corp.(TCPC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    TCP Capital (NASDAQ:TCPC)‘s stock had its “buy” rating restated by equities research analysts at National Securities in a research report issued to clients and investors on Monday. They presently have a $17.00 price objective on the investment management company’s stock. National Securities’ price target indicates a potential upside of 17.24% from the stock’s previous close.

  • [By Lee Jackson]

    This is a solid business development company (BDC) with shares that have acted well this year. Blackrock TPC Capital Corp. (NASDAQ: TCPC) is an externally managed specialty finance company focused on middle-market lending. The company has elected to be regulated as a BDC under the Investment Company Act of 1940.

  • [By Joseph Griffin]

    TCP Capital (NASDAQ:TCPC) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BlackRock TCP Capital (TCPC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Invest In Right Now: Ramco-Gershenson Properties Trust(RPT)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Ramco-Gershenson Properties Trust (RPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    Ramco-Gershenson Properties Trust  (NYSE:RPT)Q4 2018 Earnings Conference CallFeb. 21, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    ILLEGAL ACTIVITY WARNING: “Ramco-Gershenson Properties Trust (RPT) Releases FY19 Earnings Guidance” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4166975/ramco-gershenson-properties-trust-rpt-releases-fy19-earnings-guidance.html.

  • [By Max Byerly]

    Ramco-Gershenson Properties Trust (NYSE:RPT) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.

  • [By Shane Hupp]

    KeyCorp set a $15.00 price target on Ramco-Gershenson Properties Trust (NYSE:RPT) in a research note published on Wednesday. The brokerage currently has a buy rating on the real estate investment trust’s stock. KeyCorp also issued estimates for Ramco-Gershenson Properties Trust’s Q3 2018 earnings at $0.32 EPS, Q4 2018 earnings at $0.32 EPS, FY2018 earnings at $1.29 EPS, Q1 2019 earnings at $0.32 EPS, Q2 2019 earnings at $0.31 EPS, Q3 2019 earnings at $0.32 EPS, Q4 2019 earnings at $0.32 EPS and FY2019 earnings at $1.27 EPS.

  • [By Joseph Griffin]

    Ramco-Gershenson Properties Trust (NYSE:RPT) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Top 5 Clean Energy Stocks To Invest In Right Now: Syndax Pharmaceuticals, Inc. (SNDX)

Advisors’ Opinion:

  • [By Shane Hupp]

    Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Syndax (SNDX) is developing entinostat, a Class I HDAC inhibitor, for the treatment of solid tumors. Shares popped recently following the release of Syndax’s first quarter earnings results, but a bigger catalyst on the horizon is the upcoming ASCO oncology conference in June. Syndax is due to present updated data from the ENCORE-601 Phase 2 trial in melanoma and lung cancer.

  • [By Logan Wallace]

    Several institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $28,326,000. Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after buying an additional 82,256 shares during the period. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after buying an additional 22,803 shares during the period. Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after buying an additional 29,607 shares during the period. Finally, State Street Corp grew its position in shares of Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after buying an additional 20,106 shares during the period. Institutional investors own 69.55% of the company’s stock.

    TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Rating Lowered to D at TheStreet” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3364448/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.

    About Syndax Pharmaceuticals

  • [By Logan Wallace]

    A number of brokerages have recently issued reports on SNDX. B. Riley began coverage on shares of Syndax Pharmaceuticals in a research report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 price target on the stock. ValuEngine downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $16.25.

    COPYRIGHT VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Thursday” was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/4188416/syndax-pharmaceuticals-sndx-set-to-announce-earnings-on-thursday.html.

    About Syndax Pharmaceuticals

  • [By Jon C. Ogg]

    Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) was started with a Buy rating and assigned a $30 price target at H.C. Wainwright on July 12. This is a small $175 million market cap company at the time of the call, but the price target in this call was about 300% higher than the $7.10 closing price. Syndax has a 52-week range of $6.61 to $15.20, and its most recent closing price was $7.49. The cancer pipeline has been the focus for such large upside here, and at one point one analyst was pointing to Syndax rallying to as high as $40.

Top 5 Clean Energy Stocks To Invest In Right Now: Cohen & Steers Quality Income Realty Fund Inc(RQI)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Cohen & Steers Quality Income Realty Inc (NYSE:RQI) declared a monthly dividend on Monday, June 18th, Wall Street Journal reports. Shareholders of record on Wednesday, August 22nd will be given a dividend of 0.08 per share by the real estate investment trust on Friday, August 31st. This represents a $0.96 annualized dividend and a yield of 7.66%. The ex-dividend date is Tuesday, August 21st.

  • [By Ethan Ryder]

    First Republic Investment Management Inc. purchased a new position in shares of Cohen & Steers Quality Income Realty Inc (NYSE:RQI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 32,456 shares of the real estate investment trust’s stock, valued at approximately $390,000.